KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBIT (2016 - 2025)

Historic EBIT for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $141.8 million.

  • Medpace Holdings' EBIT rose 2630.64% to $141.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $507.0 million, marking a year-over-year increase of 2402.86%. This contributed to the annual value of $446.9 million for FY2024, which is 3267.13% up from last year.
  • Per Medpace Holdings' latest filing, its EBIT stood at $141.8 million for Q3 2025, which was up 2630.64% from $126.3 million recorded in Q2 2025.
  • Medpace Holdings' EBIT's 5-year high stood at $141.8 million during Q3 2025, with a 5-year trough of $42.4 million in Q2 2021.
  • Its 5-year average for EBIT is $86.5 million, with a median of $84.9 million in 2023.
  • In the last 5 years, Medpace Holdings' EBIT dropped by 24.19% in 2021 and then skyrocketed by 4489.42% in 2022.
  • Medpace Holdings' EBIT (Quarter) stood at $54.9 million in 2021, then surged by 39.33% to $76.4 million in 2022, then grew by 14.25% to $87.3 million in 2023, then surged by 43.58% to $125.4 million in 2024, then grew by 13.1% to $141.8 million in 2025.
  • Its EBIT was $141.8 million in Q3 2025, compared to $126.3 million in Q2 2025 and $113.5 million in Q1 2025.